Fairvalue-Calculator Fairvalue-Calculator
EN DE

DRGEM Corporation (263690) Fair Value & Analysis

Healthcare · KR · Market cap 56.2B KRW

Price4,875 KRW
Fair Value13,688 KRW
Upside+180.8%
Quality95/100
Evidence: High Range 9,186 KRW – 17,110 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

DRGEM Corporation (263690) currently trades at 4,875 KRW, while our model-based Fair Value estimate is 13,688 KRW — implying the stock looks roughly 180.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

DRGEM Corporation manufactures and sells diagnostic radiography systems. It offers high frequency X-ray generators; conventional and digital radiography systems; and ACQUIDR, a digital imaging system. DRGEM Corporation exports its products. The company was founded in 2003 and is headquartered in Gwangmyeong-si, South Korea.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +19%

Frequently asked questions

Is DRGEM Corporation (263690) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 13,688 KRW versus a price of 4,875 KRW — about +181% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 263690?
Our 21-model fair value for DRGEM Corporation is 13,688 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 4,875 KRW.
What is the quality score of 263690?
DRGEM Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.